Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
Inhibiting excessive inflammation at the injury site, reducing further damage to myofibers by inflammatory factors, and creating a favorable microenvironment for muscle repair
useful for upper GI targeting Troches buccal absorption, limited evidence specific to BPC-157 Who oral delivery is best suited for: Leaky gut / intestinal permeability Inflammatory bowel disease (IBD, Crohn's, ulcerative colitis) NSAID-induced gastric damage or ulcers Irritable bowel syndrome (IBS) General GI maintenance alongside other therapies Patients who cannot or will not self-inject Practical considerations: Oral bioavailability is lower for systemic goals do not expect injection-equivalent tendon or joint results Dosing protocols typically require three to ten times the injectable dose to achieve comparable GI effects Product quality varies widely in the oral supplement market sourcing from a licensed compounding pharmacy is essential Nasal BPC-157: Emerging Option, Limited Evidence Nasal BPC-157 is the third delivery route and the least established
If you are lean with less subcutaneous tissue, use a 45-degree angle to reduce the chance of hitting muscle
Protocol bundles are available: 3-month protocol for $635 ($212/mo, save $115) or 6-month protocol for $1,200 ($200/mo, save $300)
The certified WHO-GMP ISO DCGI manufacturer should be selected from available options
US$ 25.64
US$ 23.84
US$ 24.53
US$ 23.00
US$ 21.23